Neurofibromatosis type 1 (NF1) is a rare, complex, and often under-recognized condition that presents significant diagnostic and management challenges, particularly for oncology nurses who play a central role in longitudinal patient care. Despite recent advances, including…

Antibody-drug conjugates (ADCs) are redefining precision oncology by delivering potent therapies directly to tumor cells through highly specific molecular targeting. This innovative approach is rapidly becoming a cornerstone of cancer care, particularly in metastatic non-small cell…

Despite significant advances in the management of advanced or recurrent endometrial cancer (EC)—including the use of molecular classification, immune checkpoint inhibitors, and targeted therapies—delivering timely, guideline-compliant care remains complex. Rapidly evolving clinical evidence, the growing role…

Neurofibromatosis type 1 (NF1) is a common autosomal dominant genetic disorder characterized by tumor predisposition and a wide spectrum of neurologic manifestations. Among its most serious complications are plexiform neurofibromas (PNs), which can cause significant morbidity…

Immune checkpoint inhibitors (ICIs) have transformed the landscape of oncology, achieving remarkable outcomes across tumor types. As outcomes improve and focus shifts to patient-centered care, however, the burden of ongoing treatment continues to impact patient quality…

Access Transcript | Access Slides | Obtain Credit | For More Information

Access Transcript | Access Slides | Obtain Credit | For More Information

We explore how new non‑factor options and high‑sustained factor products are changing hemophilia care and why shared decision making leads to better, more flexible lives. We connect treatment choice to joint health, mental health, aging, and…

Access Transcript | Access Slides | Obtain Credit | For More Information

Access Transcript | Access Slides | Obtain Credit | For More Information

Neurofibromatosis type 1 (NF1) treatment options and management strategies are evolving, and the multiplicity of clinical manifestations, both near- and long-term, makes diagnosis and management of the disease complex. The development of plexiform neurofibromas (PNs) further…

 | Neurofibromatosis type 1 (NF1) presents unique diagnostic and management challenges due to its multisystem involvement and complex neuro-oncologic manifestations. Despite recent advances, including the use of mitogen-activated protein kinase inhibitors, many neurology and neuro-oncology clinicians…

 | Desmoid tumors (DTs) are rare, locally invasive neoplasms that present significant challenges due to their variable presentation, diagnostic delays, and the evolving therapeutic landscape. Oncology nurses and nurse practitioners often lack sufficient training in identifying…

 As the use of immunotherapies for the treatment of cancer expands, emergency medicine (EM) clinicians will need a further understanding of their mechanisms of action (MOAs) to better guide diagnosis and treatment of patients who present…

In this enduring CEC ONS Chapter installment, expert faculty will review emerging data on ADC use for HER2-neg MBC and share insights and strategies on the impact of AEs associated with ADC use and approaches to…

In this CE Concepts Grand Rounds series, expert faculty will examine the evolving treatment landscape for advanced cervical cancer and discuss how they develop individualized treatment plans that apply current guideline recommendations, consider new treatment methods,…

In this CEC Oncology recorded, case-based symposium, expert faculty will discuss diagnosis and disease challenges over a person’s lifespan; explore the integration of MEK inhibitors in the management of NF1-associated PNs in pediatric patients; and consider…

In this virtual CE Concepts Grand Rounds, expert faculty will discuss strategies to better integrate diagnostic and prognostic biomarkers for DLBCL, utilize an evidence-based approach for personalizing treatment for patients with R/R DLBCL, and identify and…

In this CE Concepts Grand Rounds podcast, expert faculty will explore the latest clinical trial data on novel treatment options for patients with resistant/recurrent (R/R) CLL/SLL, utilization of an evidence-based approach for personalizing treatment for patients…

Peripheral T-cell lymphomas (PTCLs) are a diverse collection of non-Hodgkin lymphomas that make treatment and patient-centered care challenging, and highlight the need for targeted therapies based on molecular and genetic profiling to enhance treatment efficacy and…

The reduced incidence of cervical cancer over the past few decades was primarily due to robust screening guidelines and vaccinations. However, despite the proliferation of screening programs, the diagnosis of cervical cancer is associated with inefficiencies…

Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway inhibition is the standard of care for patients with symptomatic myelofibrosis (MF); however, a significant number of hematologists/oncologists lack knowledge, competence, and confidence about JAK inhibitors (JAKis)…

The treatment paradigm in bladder cancer has fundamentally changed over the past decade, and the evolving, dense clinical trial landscape has given rise to barriers to optimizing patient care. This webcast will focus on emerging trial…

Patients with triple-negative and HR-positive/HER2-negative breast cancer have limited treatment options after the development of endocrine resistance. This dearth of options is particularly acute for Black women and other marginalized patients and results in treatment disparities….

Patients with triple-negative breast cancer (TNBC), and those with HR-positive/HER2-negative breast cancer after the development of endocrine resistance, have limited treatment options. Black women are diagnosed more often with TNBC and feel the lack of treatment…

Patient prognosis for endometrial cancer (EC) is highly benefited by molecular profiling, and national and international guidelines robustly recommend its integration into practice. Characterization of DNA mismatch repair (MMR) status identifies clinically significant molecular subtypes. This…

Reducing barriers to adequate anticoagulation for patients with cancer improves outcomes for those with cancer-associated venous thromboembolisms (CA-VTEs).  Advances in cancer treatments and the resulting improvements in patient survival have led to an increase in the…

This podcast focuses on educating, informing, and empowering clinicians involved in the care of patients with triple-negative breast cancer (TNBC) to positively impact the racial/ethnic disparities that negatively impact Black women. Our faculty will explore strategies…

To receive up to 1.0 CME/CE credit please complete the evaluation and request form here:  https://www.ceconcepts.com/activity/primary-care-perspectives-on-obesity-embracing-novel-agents-to-optimize-patient-outcomes-2/ This podcast reviews the etiology and epidemiology of obesity, as well as prominent unmet needs and barriers to treatment optimization…

To receive up to 1.0 CME/CE credit please complete the evaluation and request form here:  https://www.ceconcepts.com/igan-ee-podcast This activity will take learners on a deep dive into the pathophysiology of proteinuric glomerular disease, with an incisive focus…

This educational session will comprehensively evaluate the current state of the bladder cancer management paradigm and investigate the emergence of new data across the totality of the disease continuum, with a particular emphasis on evidence-based treatment…

This educational activity will meet nephrology nurses where they are and provide them with expert insights into CKD-aP prevalence, patient burden, therapeutic rationale, and pivotal principles for safely and effectively integrating novel treatments into practice. The…

To receive up to 1.0 CME/CE credit please complete the evaluation and request form here: https://www.ceconcepts.com/navigating-ckd-podcast#group-tabs-node-course-default1 To facilitate timely diagnosis and rapid treatment initiation for anemia in CKD, the multidisciplinary and interprofessional CKD-anemia treatment team should…

To receive up to 1.0 CME/CE credit please complete the evaluation and request form here: https://www.ceconcepts.com/hk-ch-podcast Learning Objectives Appraise key mechanisms of potassium homeostasis and review patient-centric risk factors for hyperkalemia. Discuss the prevalence and clinical gravity…

To receive up to 1.0 CME/CE credit please complete the evaluation and request form here: https://www.ceconcepts.com/sitc22-podcast This session will review the totality of emerging evidence for immune checkpoint inhibitors (ICIs) in the hepatocellular carcinoma (HCC) and…

To receive up to 1.0 CME/CE credit please complete the evaluation and request form here: https://www.ceconcepts.com/iv-iron-expert-exchange-podcast In this Expert Exchange-based format, activity attendees will be immersed in a lively discussion between key thought leaders in the…

To receive up to 2.0 CME/CE credit please complete the evaluation and request form here: https://www.ceconcepts.com/2022chest-podcast This dynamic live symposium, led by top experts in the field of pulmonary medicine and NSCLC, will take attendees on…

To receive up to 1.0 CME/CE credit please complete the evaluation and request form here: https://www.ceconcepts.com/ebc-gr-podcastLearning Objectives Review the epidemiology and clinical characteristics of HR+, HER2- early-breast cancer (EBC), and identify patients at an elevated risk…

To receive up to 1.0 CME/CE credit please complete the evaluation and request form here: https://www.ceconcepts.com/ovarian-gr-podcast Learning Objectives Review recent updates to national guideline recommendations in ovarian cancer treatment and testing and discuss health equity issues…

To receive up to 1.0 CME/CE credit please complete the evaluation and request form here: https://www.ceconcepts.com/iv-gr-podcast#group-tabs-node-course-default1 Learning Objectives Review the clinical gravity and foundational pathophysiology of iron deficiency anemia (IDA) in pediatric patients, with an emphasis…

Join our Expert Faculty, Drs. Joel W. Neal, MD, PhD and Victoria Sherry, DNP, CRNP, AOCNP as they discuss treatment principles across the continuum of care in unresectable, stage III NSCLC. During their presentations and discussion,…

Learning Objectives Review the formative facets of iron absorption and metabolism, including the practical distinctions between functional and absolute iron deficiency, with expert analysis of how these principles dictate treatment approaches. Summarize the multifactorial etiologies and…

All clinicians managing patients with non-dialysis-dependent chronic kidney disease or heart failure must be aware of the deleterious impacts of concomitant anemia and the established, emerging, and practice-changing role of intravenous (IV) iron therapies. The vicious…

This Rapid Recap will provide a responsive, timely, and incisive overview of data presented at the 2022 Clinical Oncology Annual Meeting, and offer expert insights into the shifting management landscape for metastatic EGFR+ NSCLC. These data…

Learning Objectives Discuss the multifaceted etiology of the racial disparity observed in triple-negative breast cancer (TNBC), with a focus on both biologic and non-biologic factors, and identify tangible strategies community-based clinicians can employ to promote equitable…

This symposium will explore the latest ovarian cancer guideline recommendations and recent evidence for PARP inhibitors in treatment and maintenance settings. The nurse’s role in facilitating access to quality care for those with disparities, the unique…

This activity will review the failure rates of traditional therapies for DLBCL, such as R-CHOP, and evaluate patient-centric factors that contribute to disease progression and/or relapse. Expert faculty will then guide attendees through an evidence-based examination…

This activity will review how social determinants of health have led to inequities and disparate outcomes in HF. Attendees will take part in an expert-led exploration of current treatment guidelines, with an emphasis on HFrEF, and…

Credit is no longer available, however, you can still access and learn from this podcast! This Medical Moments webinar will review all clinically relevant aspects of cancer-related anemia (CRA) management, including chemotherapy-induced anemia (CIA). The activity…

Our hosts interview two pharmacists, both of whom have expertise in the realms of vaccine supply chain management, distribution, and administration, regarding the myriad challenges and practical hurdles posed by a global pandemic – and key…

Our hosts interview an immunology researcher and vaccine expert regarding how effectively harnessing the immune system possesses the power to defeat the pandemic and restore normalcy to the world. Practical issues, such as the role of…

An infectious disease pharmacist and an immunology specialty pharmacist discuss current and emerging data about COVID-19 with a renowned virologist. They review where we've been, the current state of affairs as the vaccine supply chain is…